Coherus Oncology (CHRS) Other Non Operating Income (2016 - 2025)
Historic Other Non Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $2.1 million.
- Coherus Oncology's Other Non Operating Income rose 273.51% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 16698.69%. This contributed to the annual value of -$12.6 million for FY2024, which is 33093.8% down from last year.
- According to the latest figures from Q3 2025, Coherus Oncology's Other Non Operating Income is $2.1 million, which was up 273.51% from $2.9 million recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Other Non Operating Income registered a high of $2.9 million during Q2 2025, and its lowest value of -$12.6 million during Q2 2024.
- In the last 5 years, Coherus Oncology's Other Non Operating Income had a median value of $443000.0 in 2022 and averaged -$100117.6.
- Within the past 5 years, the most significant YoY rise in Coherus Oncology's Other Non Operating Income was 436333.33% (2022), while the steepest drop was 1030000.0% (2022).
- Coherus Oncology's Other Non Operating Income (Quarter) stood at -$385000.0 in 2021, then soared by 447.79% to $1.3 million in 2022, then tumbled by 109.63% to -$129000.0 in 2023, then surged by 1715.5% to $2.1 million in 2024, then increased by 2.74% to $2.1 million in 2025.
- Its Other Non Operating Income stands at $2.1 million for Q3 2025, versus $2.9 million for Q2 2025 and $187000.0 for Q1 2025.